The revenue miss and decelerating growth temper the EPS beat and guidance raise. Watch for execution on the OneOncology integration and the MWI/Covetrus merger to drive margin expansion in H2. The $1B buyback signals management confidence but is not a catalyst on its own given slowing top-line momentum.
Price Chart
Executive Summary
Cencora reported fiscal Q2 2026 adjusted diluted EPS of $4.75, slightly above the $4.73 consensus estimate, on revenue of $78.4B (below the $81.04B consensus). The company raised its full-year adjusted EPS guidance range to $17.65-$17.90 from $17.45-$17.75 and announced a $1B share repurchase plan. However, revenue growth decelerated to 3.8% YoY (vs 5.5% in Q1), and adjusted operating income growth slowed to 6.0% (vs 11.9% in Q1), signaling maturing momentum in the core distribution business.
Key Financial Metrics
Key Facts
- Adjusted diluted EPS of $4.75 vs consensus $4.73 (beat by 0.4%)
- Revenue of $78.4B vs consensus $81.04B (miss by 3.3%)
- Revenue growth slowed to 3.8% YoY from 5.5% in Q1
- Adjusted operating income growth slowed to 6.0% from 11.9% in Q1
- Full-year adjusted EPS guidance raised to $17.65-$17.90 from $17.45-$17.75
- Company expects to repurchase $1B in shares by end of calendar 2026
- Quarterly dividend maintained at $0.60 per share
- Completed acquisition of OneOncology in February 2026
- Signed definitive agreement to merge MWI Animal Health with Covetrus
- Signed definitive agreement to acquire EyeSouth Partners retina business
Financial Impact
Adjusted EPS beat by $0.02 (0.4%); revenue miss of ~$2.6B (3.3%); guidance raised by $0.15-$0.20 at midpoint
Risk Factors
- Revenue growth deceleration to 3.8% from 5.5% signals maturing core distribution business
- Revenue miss of 3.3% vs consensus may pressure the stock near-term
- Interest expense increased 35.1% YoY due to debt-financed acquisitions
- Operating cash flow negative $966.5M in H1 due to working capital needs
- International segment operating income declined 0.6% on a six-month basis
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140859-26-000018 |
| Document: abc-20260506.htm | 0001140859-26-000018 |
| Document: 0001140859-26-000018-index-headers.html | 0001140859-26-000018 |
| Document: 0001140859-26-000018-index.html | 0001140859-26-000018 |
| Document: 0001140859-26-000018.txt | 0001140859-26-000018 |
| 8-K Data (Synthetic) | 0001140859-26-000018 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Institutional Cluster | $318.04 $308.78 | ▼ −2.91% | ▼ −2.63% | $304.47 (−4.27%) |
Aug 5, 2026 8w ago | 8-K | $317.22 $336.36 | ▲ +6.03% | ▲ +6.64% | $304.47 (−4.02%) |
Aug 5, 2026 8w ago | 8-K | $317.22 $336.36 | ▲ +6.03% | ▲ +6.64% | $304.47 (−4.02%) |
Jun 15, 2026 15w ago | 8-K | $281.46 $302.28 | ▲ +7.40% | ▲ +7.20% | $304.47 (+8.18%) |
May 29, 2026 17w ago | 8-K | $264.69 $282.98 | ▲ +6.91% | ▲ +8.21% | $304.47 (+15.03%) |
May 6, 2026 21w ago | 8-K | $252.74 $263.64 | ▲ +4.31% | ▲ +1.53% | $304.47 (+20.47%) |
Feb 28, 2026 30w ago | Institutional Cluster | $372.65 $309.93 | ▼ −16.83% | ▼ −8.89% | $304.47 (−18.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access